
    
      This study hypothesizes that the combination of Floxuridine (FUDR), a type of chemotherapy,
      delivered via a hepatic artery infusion (HAI) pump, with standard of care systemic
      chemotherapy will lead to improved survival in the treatment of pancreatic cancer liver
      metastases. Patients will receive 6 cycles of FUDR and will be followed for two years.
    
  